GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rohto Pharmaceutical Co Ltd (TSE:4527) » Definitions » Piotroski F-Score

Rohto Pharmaceutical Co (TSE:4527) Piotroski F-Score : 7 (As of Apr. 27, 2024)


View and export this data going back to 1962. Start your Free Trial

What is Rohto Pharmaceutical Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rohto Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Rohto Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

TSE:4527' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Rohto Pharmaceutical Co was 8. The lowest was 2. And the median was 5.


Rohto Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Rohto Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rohto Pharmaceutical Co Piotroski F-Score Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 8.00 5.00 5.00 7.00

Rohto Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 7.00 - - -

Competitive Comparison of Rohto Pharmaceutical Co's Piotroski F-Score

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rohto Pharmaceutical Co's Piotroski F-Score Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was 円26,377 Mil.
Cash Flow from Operations was 円30,924 Mil.
Revenue was 円238,664 Mil.
Gross Profit was 円137,421 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was (274876 + 309677) / 2 = 円292276.5 Mil.
Total Assets at the begining of this year (Mar22) was 円274,876 Mil.
Long-Term Debt & Capital Lease Obligation was 円7,516 Mil.
Total Current Assets was 円190,246 Mil.
Total Current Liabilities was 円80,162 Mil.
Net Income was 円21,127 Mil.

Revenue was 円199,646 Mil.
Gross Profit was 円116,170 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was (226149 + 274876) / 2 = 円250512.5 Mil.
Total Assets at the begining of last year (Mar21) was 円226,149 Mil.
Long-Term Debt & Capital Lease Obligation was 円13,350 Mil.
Total Current Assets was 円164,306 Mil.
Total Current Liabilities was 円71,488 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rohto Pharmaceutical Co's current Net Income (TTM) was 26,377. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rohto Pharmaceutical Co's current Cash Flow from Operations (TTM) was 30,924. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=26377/274876
=0.09595963

ROA (Last Year)=Net Income/Total Assets (Mar21)
=21127/226149
=0.09342071

Rohto Pharmaceutical Co's return on assets of this year was 0.09595963. Rohto Pharmaceutical Co's return on assets of last year was 0.09342071. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Rohto Pharmaceutical Co's current Net Income (TTM) was 26,377. Rohto Pharmaceutical Co's current Cash Flow from Operations (TTM) was 30,924. ==> 30,924 > 26,377 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=7516/292276.5
=0.02571538

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=13350/250512.5
=0.05329075

Rohto Pharmaceutical Co's gearing of this year was 0.02571538. Rohto Pharmaceutical Co's gearing of last year was 0.05329075. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=190246/80162
=2.37326913

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=164306/71488
=2.29837175

Rohto Pharmaceutical Co's current ratio of this year was 2.37326913. Rohto Pharmaceutical Co's current ratio of last year was 2.29837175. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Rohto Pharmaceutical Co's number of shares in issue this year was 228.788. Rohto Pharmaceutical Co's number of shares in issue last year was 228.796. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=137421/238664
=0.57579275

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=116170/199646
=0.58187993

Rohto Pharmaceutical Co's gross margin of this year was 0.57579275. Rohto Pharmaceutical Co's gross margin of last year was 0.58187993. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=238664/274876
=0.8682606

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar21)
=199646/226149
=0.88280735

Rohto Pharmaceutical Co's asset turnover of this year was 0.8682606. Rohto Pharmaceutical Co's asset turnover of last year was 0.88280735. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+0+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rohto Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Rohto Pharmaceutical Co  (TSE:4527) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Rohto Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Rohto Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Rohto Pharmaceutical Co (TSE:4527) Business Description

Traded in Other Exchanges
Address
1-8-1, Tatsumi-nishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.

Rohto Pharmaceutical Co (TSE:4527) Headlines

No Headlines